Chronic obstructive pulmonary disease Trials in Caba, Argentina
Conditions / Chronic obstructive pulmonary disease / Caba, Argentina
Research into Chronic obstructive pulmonary disease spans multiple therapeutic approaches and trial phases.
13 total trials for this combination
Showing top 10 of 13 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT04701983 | Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | — |
| NCT05612035 | Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD | ACTIVE_NOT_RECRUITING | — |
| NCT03930732 | Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation | COMPLETED | PHASE3 |
| NCT04701983 | Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | — |
| NCT04751487 | Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | — |
| NCT04751487 | Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | — |
| NCT05612035 | Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD | ACTIVE_NOT_RECRUITING | — |
| NCT05878769 | A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | RECRUITING | PHASE3 |
| NCT04053634 | Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations | COMPLETED | PHASE3 |
| NCT04456673 | Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation | COMPLETED | PHASE3 |